therapeutics

Response to: ‘Correspondence on ‘Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort’ by Pouletty et al’ by Pino et al
Naim Ouldali, Marie Pouletty, Johanna Lokmer, Cherine Benzouid, Constance Beyler, Anna Deho, Ulrich Meinzer, Albert Faye, Isabelle Melki

Annals of the Rheumatic Diseases Aug 2020, annrheumdis-2020-218614; DOI: 10.1136/annrheumdis-2020-218614
Targeting IL-6 in COVID-19. Response to: ‘Rational use of tocilizumab in COVID-19’ by Jain and Sharma
Pier Leopoldo Capecchi, Pietro Enea Lazzerini

Annals of the Rheumatic Diseases Jul 2020, annrheumdis-2020-218627; DOI: 10.1136/annrheumdis-2020-218627
Targeting IL-1, IL-6 or GM-CSF in COVID-19. Response to: ‘More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia’ by Ferraccioli
Emanuel Della-Torre, Corrado Campochiaro, Giulio Cavalli, Giacomo De Luca, Fabio Ciceri, Alberto Zangrillo, Lorenzo Dagna

Annals of the Rheumatic Diseases Jul 2020, annrheumdis-2020-218612; DOI: 10.1136/annrheumdis-2020-218612
The use of tocilizumab and tofacitinib in patients with resolved hepatitis B infection: a case series
Naomi Serling-Boyd, Amir M Mohareb, Arthur Y Kim, Emily P Hyle, Zachary S Wallace

Annals of the Rheumatic Diseases Jul 2020, annrheumdis-2020-218289; DOI: 10.1136/annrheumdis-2020-218289
Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome
Mirko Scarsi, Silvia Piantoni, Enrico Colombo, Paolo Airó, Donata Richini, Marco Miclini, Valeria Bertasi, Marta Bianchi, Damiano Bottone, Patrizia Civelli, Maria-Sofia Cotelli, Ezio Damiolini, Gloria Galbassini, Diego Gatta, Maria-Laura Ghirardelli, Roberto Magri, Paola Malamani, Monia Mendeni, Stefano Molinari, Andrea Morotti, Luisa Salada, Marinella Turla, Angiola Vender, Angela Tincani, Antonio Brucato, Franco Franceschini, Roberto Furloni, Laura Andreoli

Annals of the Rheumatic Diseases Jul 2020, annrheumdis-2020-217712; DOI: 10.1136/annrheumdis-2020-217712
EULAR PsA management recommendations 2019: can the recommendations be improved?
Roy M Fleischmann

Annals of the Rheumatic Diseases Jun 2020, 79 (6) 700-712; DOI: 10.1136/annrheumdis-2020-217236
Response to: ‘Clinical features of patients with rheumatic diseases and COVID-19 infection in Sarawak, Malaysia’ by Wan et al
Jixin Zhong, Lingli Dong

Annals of the Rheumatic Diseases Jul 2020, annrheumdis-2020-218441; DOI: 10.1136/annrheumdis-2020-218441
Response to: ‘Comment on Ye et al ‘Presence of respiratory failure of COVID-19 infection in patients with rheumatism in Wuhan, China’’ by Chen et al
Jixin Zhong, Cong Ye, Shaozhe Cai, Lingli Dong

Annals of the Rheumatic Diseases Jul 2020, annrheumdis-2020-218508; DOI: 10.1136/annrheumdis-2020-218508
Response to: ‘Impact of COVID-19 pandemic on patients with SLE: results of a large multicentric survey from India’ by Goyal et al
Alexis Mathian, Zahir Amoura

Annals of the Rheumatic Diseases Jul 2020, annrheumdis-2020-218146; DOI: 10.1136/annrheumdis-2020-218146
Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study
Emanuel Della-Torre, Corrado Campochiaro, Giulio Cavalli, Giacomo De Luca, Angela Napolitano, Salvatore La Marca, Nicola Boffini, Valentina Da Prat, Gaetano Di Terlizzi, Marco Lanzillotta, Patrizia Rovere Querini, Annalisa Ruggeri, Giovanni Landoni, Moreno Tresoldi, Fabio Ciceri, ALberto Zangrillo, Francesco De Cobelli, Lorenzo Dagna

Annals of the Rheumatic Diseases Jul 2020, annrheumdis-2020-218122; DOI: 10.1136/annrheumdis-2020-218122

Main menu

therapeutics

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

therapeutics

Pages